EPO and Alzheimer disease: A recombinant human erythropoietin, which lacks erythropoietic activity due to its low sialic acid content, exhibits a shorter plasma half-life. This drug has the potential to prevent oxidative damage, neuroinflammation, apoptosis, and cognitive deficits in models of AD.